'You Can't Be Bought for the Price of a Sandwich.' Cochrane Just Tested That.

The Physician Payments Sunshine Act of 2010 did something unusual: it forced drug and device makers to publish the money they hand to doctors. More than a decade of that public ledger has now been assembled into a systematic review, and the picture it produces is not flattering to the profession's self-image.

What 93 Studies Add Up To

Published October 8 in the Cochrane Database of Systematic Reviews, the analysis pulls together 93 studies — 88 percent of them from the United States, a concentration the authors attribute directly to the Sunshine Act's searchable payment database. Analyzing millions of prescribers, the team sorted industry contact into three buckets: advertising and education such as sales representative visits, gifts and payments including paid meals and speaking fees, and free drug samples. Conflict-of-interest policies were assessed separately, as a possible brake. Almost all included studies observed real prescribing in clinical practice rather than running controlled experiments, so the findings describe what happens in exam rooms rather than what could happen under ideal conditions.

Gifts and payments produced the strongest and most consistent evidence: less appropriate prescribing, a higher volume of prescriptions and probably higher costs. Advertising and education showed a similar negative association, with fairly strong evidence that sales rep visits also raised the number of prescriptions written. The evidence on free samples was too thin to draw conclusions.

What gives the finding its weight is a dose-response relationship. The more paid meals a physician received from a particular company, the more of that company's drug they prescribed — a gradient that held across therapeutic classes as divergent as antihypertensives, statins, antidepressants and opioid painkillers, and one that is hard to explain away by confounding. "Physicians often think that this is trivial and doesn't influence them, that they 'can't be bought for the price of a sandwich,'" said lead author Barbara Mintzes of the University of Sydney. "But the data shows this is an effective marketing strategy."

The Opioid Case, and the One Lever That Worked

The opioid crisis is where the review places its heaviest example. Even inexpensive meals were associated with increased opioid prescribing, and the more payments a physician received from opioid manufacturers, the more likely they were to prescribe dangerously high doses. Co-author Lisa Bero of the University of Colorado Anschutz called that overprescribing "perhaps the most egregious example" of the phenomenon, then declined to treat it as an outlier: the systems that produced it, she said, "are unfortunately considered business-as-usual within the industry."

The review's counterpoint is actionable. Institutions with robust conflict-of-interest policies limiting rep access and gifts tended to show improved prescribing appropriateness, and the authors frame the problem as structural rather than a matter of a few bad actors. For patients already in or seeking opioid addiction treatment, the implication has not changed in fifteen years: the first prescription is usually written long before anyone uses the word dependence, and the evidence says whose interest shaped it is knowable.